Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2007 Mar;52(3):732-6.
doi: 10.1007/s10620-006-9457-x.

Pegylated interferon and ribavirin failures: is retreatment an option?

Rekha Cheruvattath  1 , Marianne J Rosati, Manjushree Gautam, Hugo E Vargas, Jorge Rakela, Vijayan Balan
Affiliations
Case Reports

Pegylated interferon and ribavirin failures: is retreatment an option?

Rekha Cheruvattath et al. Dig Dis Sci. 2007 Mar.

Abstract

Currently, there are limited therapeutic options available for chronic hepatitis C (HCV) patients who fail treatment with peginterferon alpha (PEG IFN) + ribavirin (RBV). An option is retreatment with a second course PEG-IFN + RBV. However, the virologic clearance with this option is unknown. Thus, we evaluated the outcome of our cohort of patients with chronic HCV who achieved a sustained viral response when retreated with PEG IFN plus RBV after having no response to an initial course of PEG IFN plus RBV. Nonresponse to treatment was defined as failure to achieve an early virologic response by week 12 or presence of detectable HCV RNA at week 24 or after completion of PEG-IFN + RBV therapy. Twenty patients (12 [60%] men; 8 [40%] women) were treated with PEG IFN alpha-2b plus RBV and PEG IFN alpha-2a plus RBV. The mean age of the patients was 50 years, 85% were white, 95% had genotype 1, and 35% had cirrhosis. Prior to the first course of PEG IFN plus RBV, 12 (60%) of 20 patients had no prior treatment for Hepatitis C. After the second course of PEG IFN plus RBV, 2 (10%) of 20 patients achieved a sustained virologic response. These results suggest marginal benefit of retreatment of patients with chronic HCV with another course of PEG IFN plus RBV after they have not responded to an initial course of PEG IFN plus RBV.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gastroenterology. 1997 Nov;113(5):1647-53 - PubMed
    1. J Viral Hepat. 2004 Nov;11(6):543-51 - PubMed
    1. Curr Gastroenterol Rep. 2000 Feb;2(1):11-7 - PubMed
    1. Hepatology. 2004 Apr;39(4):1147-71 - PubMed
    1. J Viral Hepat. 2002 May;9(3):202-7 - PubMed

Publication types

LinkOut - more resources